| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.096 | 0.04 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.04 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.091 | 0.04 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.05 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.05 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.062 | 0.05 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.067 | 0.05 |